SCHEMBL9516951

SCHEMBL9516951

COCc1ccc(C(=O)NC(=O)Nc2ccccc2)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.52
RAB9A P51151 7/20 0.52
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
P4HTM Q9NXG6 2/20 0.46
CASP3 P42574 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SMO Q99835 1/20 0.45
AHR P35869 1/20 0.44
NPSR1 Q6W5P4 1/20 0.42
PDGFRB P09619 1/20 0.41
KDR P35968 1/20 0.41
CXCR1 P25024 1/20 0.41
CXCR2 P25025 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
GABRA5 P31644 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9566760 0.90 RAB9A (0.60) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL9515509 0.88 NPC1 (0.50) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL9515480 0.88 CXCR2 (0.52) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL9516029 0.88 NPC1 (0.50) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL9519528 0.84 RAB9A (0.58) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL3950709 0.80 BAZ2B (0.49) KMT2AMEN1P4HTMAHRMAPT
SCHEMBL9519589 0.78 CXCR2 (0.54) KMT2AMEN1P4HTMCXCR1CXCR2
SCHEMBL9519363 0.78 CXCR1 (0.43) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL9515774 0.78 NPC1 (0.47) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL9519137 0.78 NPC1 (0.54) NPC1RAB9AKMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0567997-A1 4- or 5-(sulf)imido- and (sulfon)amidopyridines and their pyridine-N-oxides, process for their preparation and their use as pharmaceutical HOECHST AKTIENGESELLSCHAFT (DE) 1993-11-03 EP disclosed